[Expert Consensus on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer]

Area of Science:

• Oncology
• Pharmacology

Background:

• Small molecule targeted drugs have improved lung cancer survival.
• Challenges include drug variety, rapid development, complex adverse reactions, and home use, increasing irrational use risks.
• Insufficient efficacy and safety monitoring can negatively impact treatment outcomes.

Purpose of the Study:

• To establish standardized recommendations for the rational use and monitoring of 43 small molecule targeted drugs or combinations for lung cancer.
• To improve the quality of efficacy and adverse reaction monitoring.
• To enhance patient compliance and quality of life.

Main Methods:

• Development of a consensus focusing on 43 small molecule targeted drugs for lung cancer.
• Formulation of standardized recommendations covering drug selection, dosage adjustment, efficacy monitoring, and adverse reaction management.
• Inclusion of strategies to improve patient compliance.

Main Results:

• Standardized recommendations for rational drug use in clinical practice.
• Guidelines for monitoring efficacy and adverse reactions of targeted lung cancer therapies.
• Strategies to improve patient adherence and overall treatment effectiveness.

Conclusions:

• The consensus aims to optimize the use of small molecule targeted drugs for lung cancer.
• Ensuring rational use and robust monitoring will improve treatment effectiveness and safety.
• The ultimate goal is to prolong survival and enhance the quality of life for lung cancer patients.